Primary intestinal aspergillosis is a rare but serious infectious complication with a high morbidity and mortality in immunocompromised patients. We report a case of 47-year old male diagnosed with acute myeloid leukaemia and started on induction chemotherapy. On day 18 of chemotherapy, he presented with an acute abdomen and underwent emergency exploratory laparotomy. Histopathological specimen revealed transmural necrosis with fungal hyphae due to aspergillosis and voriconazole was started. Serum galactomannan test done was negative. In the post-induction chemotherapy, he attained complete remission and received three cycles of consolidation with high-dose cytarabine. With this case, we would like to emphasize that early recognition of primary intestinal aspergillosis is of the utmost importance because of its fulminant clinical course. It should be included in the differential diagnosis of neutropenic patients with sudden onset abdominal pain and ongoing fever, even in the absence of a positive serum galactomannan.
INTRODUCTION
Treatment of acute myeloid leukemia with standard induction chemotherapy causes prolonged myelosuppression and mortality from invasive fungal infections. [1] The most common fungal infections are Candida, Aspergillosis, and Mucormycosis, [2] the sites being blood, lungs, paranasal sinuses. We report a rare case of intestinal perforation caused by Aspergillus.
CASE REPORT
A man aged 47 years without any co-morbidities presented with high-grade fever for a month and melena for 10 days. A hemogram suggested acute leukemia. Examination showed pallor, without lymphadenopathy or organomegaly. Systemic examination was normal. A complete blood count (CBC) showed anemia (6 g/dL), thrombocytopenia (20 × 10 9 /L), and leucocytosis (74 × 10 9 /L) with 95% myeloblasts. Peripheral blood cytochemistry showed sudan back blue and myeloperoxidase positivity of myeloblasts. Bone marrow aspiration and biopsy showed increased cellularity with 90% myeloblasts [ Figure 1 ]. Flow cytometry characterized the blasts as positive for cytoplasmic myeloperoxidase, moderate CD117, CD33, dim CD38, which was consistent with acute myeloid leukemia (AML)-M1. Cytogenetics was normal and mutation panel revealed NPM1 mutation.
He was stratified as favorable risk AML and was started on standard induction chemotherapy with 
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DISCUSSION
Availability of novel agents in the last decade and improvements in supportive care have improved outcomes in AML. [1] Remission induction chemotherapy for AML causes prolonged myelosuppression rendering patients susceptible to a wide variety of bacterial and fungal pathogens resulting in serious infections and compromising outcomes. Aspergillus species are ubiquitous saprophytic spore-producing fungi commonly found in the environment. Out of approximately 200 species, Aspergillus fumigatus is responsible for majority of cases of invasive aspergillosis. Other potential species include Aspergillus niger, Aspergillus flavus, and Aspergillus terreus. [3] Aspergillosis of the gut has been reported in association with disseminated fungal disease and rarely as a primary event. The associated mortality rate has been quoted at 47-60%, with significant rates of morbidity. [4] In contrast to Candida spp., Aspergillus spores may not survive or meet favorable conditions to develop on the mucosal surfaces of the digestive tract. However, large ulcers, such as those described as occurring after high-dose cytarabine-related mucositis, may be colonized by Aspergillus spores. Most of the times, Aspergillosis of gut is an autopsy finding, because of nonspecific clinical and radiological findings.
Patients with gastrointestinal aspergillosis can present as neutropenic enterocolitis (typhlitis), appendicitis, ileus, colonic ulcers, abdominal pain, or GI bleeding. [5] A common biomarker in clinical use for invasive aspergillosis is the galactomannan assay. Galactomannan is an Aspergillus cell wall component that is released during Aspergillus growth. The assay can be used as a surveillance marker, or as a direct diagnostic tool. A meta-analysis showed that galactomannan assay had a sensitivity of 0.71 and specificity of 0.89 for proven cases of invasive aspergillosis. [6] In the present case, serum galactomannan done twice was negative.
Raoul Herbrecht et al. compared voriconazole versus
Amphotericin B for primary therapy of invasive aspergillosis. They showed superiority of voriconazole over amphotericin B in terms of response rate, survival rate, and safety. [7] The present case reiterates diagnosing infections during induction chemotherapy in hematological malignancies so that administration of antibiotics and antifungals helps in improving the outcomes in hematological malignancies.
CONCLUSIONS
Early diagnosis of invasive fungal infections in patients with AML on induction chemotherapy is difficult but essential to reduce mortality. A high index of suspicion for invasive gastrointestinal aspergillosis in immunocompromised patients presenting with acute abdominal symptoms is needed. Early surgical intervention in addition to aggressive antifungal treatments improves outcomes. Our patient recovered with timely surgical intervention and voriconazole use.
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